Theravance Biopharma Inc 2025年季度报告

Form10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13or 15(d)of the Securities Exchange Act of 1934 during the preceding 12months (or for such shorter period thatthe registrant was required to file such reports), and (2)has been subject to such filing requirements for the past90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data Filerequired to be submitted pursuant to Rule405 of RegulationS-T (§ 232.405 of this chapter)during the preceding12months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “largeaccelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” inRule12b-2 of the Exchange Act. LargeAcceleratedFiler☐Accelerated Filer☐Non-acceleratedFiler☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use theextended transition period for complying with any new or revised financial accounting standards providedpursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of theExchange Act).Yes☐No☒ As of May 2, 2025, the number of the registrant’s outstanding ordinary shares was50,001,332. THERAVANCE BIOPHARMA,INC.TABLE OF CONTENTS PageNo. PART I. FINANCIAL INFORMATIONItem 1. Financial Statements (unaudited)3Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 20243Condensed Consolidated Statements of Operations and Comprehensive Loss for the threemonths ended March 31, 2025 and 20244Condensed Consolidated Statements of Shareholders’ Equity for the three months endedMarch 31, 2025 and 20245Condensed Consolidated Statements of Cash Flows for the three months ended March 31,2025 and 20246Notes to Condensed Consolidated Financial Statements7Item 2. Management’s Discussion and Analysis of Financial Condition and Results ofOperations17Item 3. Quantitative and Qualitative Disclosures About Market Risk25Item 4. Controls and Procedures25PART II. OTHER INFORMATIONItem 1. Legal Proceedings26Item 1A. Risk Factors27Item 6. Exhibits60Signatures61 PARTI. FINANCIAL INFORMATIONITEM1.FINANCIAL STATEMENTS THERAVANCE BIOPHARMA,INC.CONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited)(In thousands, except per share data) THERAVANCE BIOPHARMA,INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited)(In thousands, except per share data) See accompanying notes to condensed consolidated financial statements. THERAVANCE BIOPHARMA,INC.CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY(Unaudited)(In thousands) See accompanying notes to condensed consolidated financial statements. THERAVANCE BIOPHARMA,INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)(In thousands) See accompanying notes to condensed consolidated financial statements. THERAVANCE BIOPHARMA,INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) 1. Organization and Summary of Significant Accounting Policies Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) is abiopharmaceutical company primarily focused on the development and commercialization ofmedicines. The Company’s focus is to delivermedicines that make a difference®in people's lives. Basis of Presentation The Company’s condensed consolidated financial statements as of March 31, 2025 and forthe three months ended March 31, 2025 are unaudited but include all adjustments (consisting only ofnormal recurring adjustments), which are considered necessary for a fair presentation of the financialposition at such date and of the operating results and cash flows for those periods, and have beenprepared in accordance with United States (“US”) generally accepted accounting principles(“GAAP”) for interim financial information. Accordingly, they do not include all of the informationand notes required by GAAP for complete financial statements. The accompanying unauditedcondensed consolidated financial statements should be read in conjunction with the auditedconsolidated December 31, 2024 financial statements and notes thereto included in the Company’sAnnual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities andExchange Commission (“SEC”) on March 7, 2025. The results for thethree months ended March 31, 2025are not necessarily indicative of theresults to be expected for the year endingDecember31, 2025, or for any other interim period or forany future period. These condensed consolidated financial statements i